أرشيف الوسم : Healthcare Professionals

CRISPR Therapeutics and Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX-001, an investigational, autologous, Gene Editing hematopoietic stem cell therapy, for the treatment of severe Transfusion-Dependent β-Thalassaemia (TDT) and Sickle Cell Disease (SCD). As with the FDA’s breakthrough ...

A TIF-compiled document aiming to provide a division of risk levels for thalassaemia and SCD patients with regards to the ongoing COVID-19 pandemic.

  On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product REBLOZYL, intended for the treatment of adults with beta-thalassaemia or transfusion-dependent anaemia associated with myelodysplastic syndromes (MDS). The applicant for this medicinal product is Celgene Europe BV. ...

The 1st webinar for Medical Specialists organised in the context of TIF’s eThalEd online course has just arrived! Dr Antonio Piga, Professor of Paediatrics & Dean of the Medicine School at San Luigi University Hospital of the Turin University, will be the host of this introductory webinar entitled ”Access to New Therapies: Reblozyl”. ...

All the latest updates of TIF’s Vaccinations & Therapeutic Drugs Guide for COVID-19 gathered in one single document.

Nurses and other health workers are at the frontlines of COVID-19 response, putting their own health at risk to protect the broader community. This World Health Day, the World Health Organisation (WHO) honors the contribution of nurses and midwives, recognizing their vital role in keeping the world healthy. The global nursing ...

TIF continues the efforts to address the questions and concerns of its global patients’ and healthcare professionals’ community about the COVID-19 Pandemic and, in doing so, it has issued 2 brand new informational documents. The TIF-proposed Haemoglobinopathy Patient Pathway for Day Care Centres, Units and Clinics treating patients with thalassaemia ...

Therapeutic advances in β-thalassaemia have gradually led to a significant improvement in prognosis over the past few decades. As a result, patients living in areas where disease specific programmes offer access to modern therapies, experience a new era of prolonged survival that tends to reach that of the normal population. ...

  On Friday, 20 March, Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. When supported for use in COVID-19 ...

The application period for the ‘Panos Englezos Prize 2020‘ has now closed